← Back to Search

Anti-metabolites

Treatment for Lymphoblastic Lymphoma (FluTBI Trial)

Phase 2
Waitlist Available
Led By Donna E Salzman, MD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years post-transplant
Awards & highlights

FluTBI Trial Summary

This trial is testing a new stem cell transplant treatment regimen for leukemia patients that may be safer and more effective, with the goal of helping patients older than 40 or those with high-risk medical conditions.

Eligible Conditions
  • Lymphoblastic Lymphoma

FluTBI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years post transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years post transplant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Subjects Disease-free Survival
Secondary outcome measures
Number of Patients With Immune Reconstitution
Number of Subjects With Platelet Engraftment
Number of Subjects With Regimen Related Toxicity
+5 more

FluTBI Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment2 Interventions
Fludarabine, Total Body Irradiation (TBI) Fludarabine: 40 mg/m2 X 4 days TBI: TBI 2 Gy 2 times a day X 3 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fludarabine
2012
Completed Phase 3
~1100
Total Body Irradiation
2006
Completed Phase 3
~820

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,579 Previous Clinical Trials
2,275,940 Total Patients Enrolled
Donna E Salzman, MDPrincipal InvestigatorUniversity of Alabama at Birmingham
Omer H Jamy, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Bone Marrow TransplantationJournal
Impact of Cyclosporine and Methylprednisolone Dose Used for Prophylaxis and Therapy of Graft-versus-host Disease on Survival and Relapse After Allogeneic Bone Marrow Transplantation
Michallet, M, M-C Perrin, A Belhabri, L Molina, F Nicolini, JD Tigaud, J-J Sotto, D Guyotat, D Fière, and E Archimbaud. 1999. “Impact of Cyclosporine and Methylprednisolone Dose Used for Prophylaxis and Therapy of Graft-versus-host Disease on Survival and Relapse After Allogeneic Bone Marrow Transplantation”. Bone Marrow Transplantation. Springer Science and Business Media LLC. doi:10.1038/sj.bmt.1701529.
clinicaltrials.govStudy
Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia
Omer Jamy 2013. "Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01991457.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top